InsiderSignal.AI

InsiderSignal.ai

ELUT - Elutia Inc.

Insider Purchase by Rakin Kevin (Dir, 10%)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

3 weeks ago, Rakin Kevin, serving as Dir, 10% owner at Elutia Inc. (ELUT), purchased 70,000 shares at $1.06 per share, for a total transaction value of $74,200.00. Following this transaction, Rakin Kevin now holds 5,225,098 shares of ELUT.

This purchase represents a 1.00% increase in Rakin Kevin's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Friday, January 30, 2026 and publicly disclosed via SEC Form 4 filing on Monday, February 2, 2026, 3 days after the trade was made.

Elutia Inc. operates in the HEALTHCARE sector, specifically within the MEDICAL DEVICES industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Rakin Kevin

Rakin Kevin

Dir, 10%

Kevin Rakin (age 64) is the Executive Chairman of Elutia Inc. (ELUT), having served on the board since 2015 and assuming the role of Chairman in November 2015, later becoming Executive Chairman in June 2022.[[1]](https://fintool.com/app/research/companies/ELUT/people/kevin-rakin)[[2]](https://elutia.com/leadership-board/) He co-founded Elutia alongside C. Randal Mills, Ph.D., with a vision to develop regenerative medicine and biosurgical products.[[2]](https://elutia.com/leadership-board/) In January 2024, the board determined his independence under Nasdaq rules, appointing him Lead Director.[[1]](https://fintool.com/app/research/companies/ELUT/people/kevin-rakin) HighCape Partners, which he co-founded in 2013 as General Partner, holds a 26% stake in Elutia.[[1]](https://fintool.com/app/research/companies/ELUT/people/kevin-rakin)[[2]](https://elutia.com/leadership-board/) Rakin recently traded as a Dir, 10% insider at Elutia.[user_query] Rakin brings over 30 years of experience in life sciences finance and leadership, including prior roles as President of Shire Regenerative Medicine, Chairman and CEO of Advanced BioHealing (acquired by Shire for $750M in 2011), Executive-in-Residence at Canaan Partners, and co-founder, President, and CEO of Genaissance Pharmaceuticals (merged with Clinical Data in 2005).[[3]](https://ctinnovations.com/member/kevin-rakin/)[[4]](https://finance.business.uconn.edu/person/kevin-rakin/) He holds an MBA from Columbia University and B.Com/B.Com (Hons) from the University of Cape Town.[[1]](https://fintool.com/app/research/companies/ELUT/people/kevin-rakin)[[2]](https://elutia.com/leadership-board/) Current external board roles include Quantum-Si Inc., Nyxoah S.A., and others, with past service on boards like Oramed Pharmaceuticals and Histogenics Corp.[[1]](https://fintool.com/app/research/companies/ELUT/people/kevin-rakin)[[2]](https://elutia.com/leadership-board/)[[3]](https://ctinnovations.com/member/kevin-rakin/)

View full insider profile →

Trade Price

$1.06

Quantity

70,000

Total Value

$74,200.00

Shares Owned

5,225,098

Trade Date

Friday, January 30, 2026

23 days ago

SEC Filing Date

Monday, February 2, 2026

Filed 3 days after trade

HEALTHCAREMEDICAL DEVICES

About Elutia Inc.

Company Overview

No company information available
View news mentioning ELUT

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/3643551

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime